Elobixibat is primarily used in the treatment of chronic constipation, particularly in cases where other treatments have not been effective. It works by inhibiting the ileal bile acid transporter, which increases the amount of bile acids in the colon, stimulating bowel movements and relieving constipation. This makes it especially beneficial for patients with constipation-predominant irritable bowel syndrome (IBS-C) or those who require long-term management of chronic constipation. Additionally, it has shown potential in improving liver function in patients with non-alcoholic fatty liver disease (NAFLD) by reducing bile acid accumulation in the liver. Its targeted mechanism of action offers a therapeutic option with fewer systemic side effects compared to traditional laxatives.